Updates are available Correction dated 2020-02-24
Click to view Correction: https://doi.org/10.1038/s41467-020-14808-w
-
Authors
Yasumizu, Yota
Rajabi, Hasan
Jin, Caining
Hata, Tsuyoshi
Pitroda, Sean
Long, Mark D. https://orcid.org/0000-0003-1120-8176
Hagiwara, Masayuki
Li, Wei
Hu, Qiang https://orcid.org/0000-0002-4090-5539
Liu, Song
Yamashita, Nami
Fushimi, Atsushi
Kui, Ling
Samur, Mehmet
Yamamoto, Masaaki
Zhang, Yan
Zhang, Ning
Hong, Deli
Maeda, Takahiro
Kosaka, Takeo https://orcid.org/0000-0002-4371-4594
Wong, Kwok K. https://orcid.org/0000-0001-6323-235X
Oya, Mototsugu
Kufe, Donald https://orcid.org/0000-0001-5743-8888
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (ca232979, ca097098, ca166480, ca216553, ca229716)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 5 March 2019
Accepted: 20 December 2019
First Online: 17 January 2020
Change Date: 24 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: D.K. has equity interests in Genus Oncology, Reata Pharmaceuticals, Hillstream BioPharma, Nanogen Therapeutics and Victa BioTherapeutics, serves as a member of the board of directors of Nanogen and Victa, and is a paid consultant to Reata, CanBas and Victa. The other authors declare no competing interests.
